Neprilysin as a Biomarker: Challenges and Opportunities

Neprilysin (NEP) inhibition is a successful novel therapeutic approach in heart failure with reduced ejection fraction. Assessing individual NEP status might be important for gathering insights into mechanisms of disease and optimising individualised patient care. NEP is a zinc-dependent multisubstr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Noemi Pavo, Suriya Prausmüller, Philipp E Bartko, Georg Goliasch, Martin Hülsmann
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2020
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/e888015c1f514aef8dcdc4ce628d660b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e888015c1f514aef8dcdc4ce628d660b
record_format	dspace
spelling	oai:doaj.org-article:e888015c1f514aef8dcdc4ce628d660b2021-12-04T16:03:25ZNeprilysin as a Biomarker: Challenges and Opportunities10.15420/cfr.2019.212057-75592057-7540https://doaj.org/article/e888015c1f514aef8dcdc4ce628d660b2020-08-01T00:00:00Zhttps://www.cfrjournal.com/articles/neprilysin-as-a-biomarkerhttps://doaj.org/toc/2057-7540https://doaj.org/toc/2057-7559Neprilysin (NEP) inhibition is a successful novel therapeutic approach in heart failure with reduced ejection fraction. Assessing individual NEP status might be important for gathering insights into mechanisms of disease and optimising individualised patient care. NEP is a zinc-dependent multisubstrate-metabolising oligoendopeptidase localised in the plasma membrane with the catalytic site facing the extracellular space. Although NEP activity in vivo is predominantly tissue-based, NEP can be released into the circulation via ectodomain shedding and exosomes. Attempts to determine circulating NEP concentrations and activity have not yet resulted in convincingly coherent results relating NEP biomarkers to heart failure disease severity or outcomes. NEP is naturally expressed on neutrophils, opening up the possibility of measuring a membrane-associated form with integrity. Small studies have linked NEP expression on neutrophils with inflammatory state and initial data might indicate its role in heart failure with reduced ejection fraction. Future studies need to assess the regulation of systemic NEP activity, which is assumed to be tissue-based, and the relationship of NEP activation with disease state. The relationship between tissue NEP activity and easily accessible circulating NEP biomarkers and the impact of the latter remains to be established.Noemi PavoSuriya PrausmüllerPhilipp E BartkoGeorg GoliaschMartin HülsmannRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENCardiac Failure Review , Vol 6, Iss , Pp - (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Noemi Pavo Suriya Prausmüller Philipp E Bartko Georg Goliasch Martin Hülsmann Neprilysin as a Biomarker: Challenges and Opportunities
description	Neprilysin (NEP) inhibition is a successful novel therapeutic approach in heart failure with reduced ejection fraction. Assessing individual NEP status might be important for gathering insights into mechanisms of disease and optimising individualised patient care. NEP is a zinc-dependent multisubstrate-metabolising oligoendopeptidase localised in the plasma membrane with the catalytic site facing the extracellular space. Although NEP activity in vivo is predominantly tissue-based, NEP can be released into the circulation via ectodomain shedding and exosomes. Attempts to determine circulating NEP concentrations and activity have not yet resulted in convincingly coherent results relating NEP biomarkers to heart failure disease severity or outcomes. NEP is naturally expressed on neutrophils, opening up the possibility of measuring a membrane-associated form with integrity. Small studies have linked NEP expression on neutrophils with inflammatory state and initial data might indicate its role in heart failure with reduced ejection fraction. Future studies need to assess the regulation of systemic NEP activity, which is assumed to be tissue-based, and the relationship of NEP activation with disease state. The relationship between tissue NEP activity and easily accessible circulating NEP biomarkers and the impact of the latter remains to be established.
format	article
author	Noemi Pavo Suriya Prausmüller Philipp E Bartko Georg Goliasch Martin Hülsmann
author_facet	Noemi Pavo Suriya Prausmüller Philipp E Bartko Georg Goliasch Martin Hülsmann
author_sort	Noemi Pavo
title	Neprilysin as a Biomarker: Challenges and Opportunities
title_short	Neprilysin as a Biomarker: Challenges and Opportunities
title_full	Neprilysin as a Biomarker: Challenges and Opportunities
title_fullStr	Neprilysin as a Biomarker: Challenges and Opportunities
title_full_unstemmed	Neprilysin as a Biomarker: Challenges and Opportunities
title_sort	neprilysin as a biomarker: challenges and opportunities
publisher	Radcliffe Medical Media
publishDate	2020
url	https://doaj.org/article/e888015c1f514aef8dcdc4ce628d660b
work_keys_str_mv	AT noemipavo neprilysinasabiomarkerchallengesandopportunities AT suriyaprausmuller neprilysinasabiomarkerchallengesandopportunities AT philippebartko neprilysinasabiomarkerchallengesandopportunities AT georggoliasch neprilysinasabiomarkerchallengesandopportunities AT martinhulsmann neprilysinasabiomarkerchallengesandopportunities
_version_	1718372767545425920

Neprilysin as a Biomarker: Challenges and Opportunities

Ejemplares similares